Dr. Reddy's Laboratories Limited or Viridian Therapeutics, Inc.: Who Invests More in Innovation?

Dr. Reddy's vs. Viridian: R&D Investment Showdown

__timestampDr. Reddy's Laboratories LimitedViridian Therapeutics, Inc.
Wednesday, January 1, 201412402000000293000
Thursday, January 1, 2015174490000001002000
Friday, January 1, 201617834000000888000
Sunday, January 1, 20171955100000019623000
Monday, January 1, 20181826500000030421000
Tuesday, January 1, 20191560700000034794000
Wednesday, January 1, 20201541000000028304000
Friday, January 1, 20211654100000056886000
Saturday, January 1, 202217482000000100894000
Sunday, January 1, 202319381000000159765000
Monday, January 1, 202422873000000
Loading chart...

Unlocking the unknown

Innovation Investment: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, innovation is the key to staying ahead. Dr. Reddy's Laboratories Limited and Viridian Therapeutics, Inc. are two companies that exemplify this drive. Over the past decade, Dr. Reddy's has consistently outpaced Viridian in research and development (R&D) spending, investing nearly 400 times more on average. From 2014 to 2023, Dr. Reddy's increased its R&D expenses by approximately 84%, peaking in 2024 with a remarkable 2.3 trillion. In contrast, Viridian's R&D spending, while growing, remains modest, with a notable increase in 2023 to 160 million. This disparity highlights Dr. Reddy's commitment to innovation, positioning it as a leader in the industry. As we look to the future, the question remains: will Viridian close the gap, or will Dr. Reddy's continue to dominate the innovation landscape?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025